MDI-0355 (MOD-C)
Cancer (PARG inhibitor, various types)
PreclinicalActive
Key Facts
About Alivexis
Alivexis develops novel small-molecule drugs for cancer and inflammatory diseases using its proprietary computational drug discovery platform.
View full company profile